NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STAPHCILLIN (methicillin sodium) is a beta-lactam antibiotic administered via injection for the treatment of staphylococcal infections. This semi-synthetic penicillin works by inhibiting bacterial cell wall synthesis, making it bactericidal against susceptible gram-positive organisms. It represents a historical cornerstone of anti-staphylococcal therapy.
Pre-Launch
Pre-launch status indicates limited current commercial infrastructure; team building and go-to-market strategy development are primary focus areas.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on STAPHCILLIN at pre-launch represents a foundational opportunity to build commercial and medical infrastructure from inception, particularly in hospital-based infectious disease channels. Career progression depends heavily on successful regulatory approval, launch execution, and competitive differentiation in a crowded anti-infective market.
Product ManagerMedical Science Liaison
Worked on STAPHCILLIN at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.